Trial watch: DNA-based vaccines for oncological indications

OncoImmunology

Volumn 6, Issue 12, 2017, Pages

  Pierini, Stefano ^a,b   Perales Linares, Renzo ^a,b   Uribe Herranz, Mireia ^a,b   Pol, Jonathan G ^c,d,e,f   Zitvogel, Laurence ^f,g,h,i   Kroemer, Guido ^{c,d,e,f,g,j,k}   Facciabene, Andrea ^a,b   Galluzzi, Lorenzo ^c,l  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f INSERM   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h Center of Clinical Investigations in Biotherapies of Cancer (CICBT)   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

adenovirus; cancer testis antigens; CTLA4; electroporation; PADRE; PD 1; TRICOM

Indexed keywords

ADENOVIRUS VACCINE; AXALIMOGENE FILOLISBAC; BEVACIZUMAB; CANCER TESTIS ANTIGEN; CISPLATIN; DNA VACCINE; DURVALUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMATINIB; IMMUNOBODY; INVAC; METRONIDAZOLE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; PEMBROLIZUMAB; PEMETREXED; RILIMOGENE GALVACIREPVEC; TUMOR ANTIGEN; WART VIRUS VACCINE;

ANTIGEN EXPRESSION; CANCER IMMUNIZATION; DNA IMMUNIZATION; DRUG ADMINISTRATION ROUTE; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASM; MULTICENTER STUDY (TOPIC); NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VACCINE IMMUNOGENICITY;

EID: 85036507982     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1398878     Document Type: Review

References (268)

1. Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent). 2005;18:21–5.
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565–70. doi:10.1126/science.1203486.
3. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5:12472–508. doi:10.18632/oncotarget.2998.
4. Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, et al. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4:e985940. doi:10.4161/2162402X.2014.985940. PMID:25949870.
5. Chaganty BK, Lu Y, Qiu S, Somanchi SS, Lee DA, Fan Z. Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNgamma secretion. Oncoimmunology. 2016;5:e1100790. doi:10.1080/2162402X.2015.1100790. PMID:27141382.
6. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, et al. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018. In press.
7. Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of Metastasis by NK Cells. Cancer Cell. 2017;32:135–54. doi:10.1016/j.ccell.2017.06.009.
8. Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology. 2016;5:e1106127. doi:10.1080/2162402X.2015.1106127. PMID:26942094.
9. Rekoske BT, Olson BM, McNeel DG. Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology. 2016;5:e1165377. doi:10.1080/2162402X.2016.1165377. PMID:27471641.
10. Jelinek T, Hajek R. PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future. Oncoimmunology. 2016;5:e1254856. doi:10.1080/2162402X.2016.1254856. PMID:28123899.
11. Buque A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, et al. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4:e1008814. doi:10.1080/2162402X.2015.1008814. PMID:26137403.
12. Kroemer G, Galluzzi L. Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. Oncoimmunology. 2015;4:e1008853. doi:10.1080/2162402X.2015.1008853. PMID:26155425.
13. Kroemer G, Galluzzi L. Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology. 2015;4:e1058037. doi:10.1080/2162402X.2015.1058037. PMID:26140249.
14. Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–84. doi:10.1126/science.aad1329.
15. Gulley JL, Mulders P, Albers P, Banchereau J, Bolla M, Pantel K, Powles T. Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. Oncoimmunology. 2016;5:e1107698. doi:10.1080/2162402X.2015.1107698. PMID:27141392.
16. Wei XX, Fong L, Small EJ. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. Expert Rev Vaccines. 2015;14:1529–41. doi:10.1586/14760584.2015.1099437.
17. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22. doi:10.1056/NEJMoa1001294.
18. First-Ever CAR T-cell Therapy Approved in U.S. Cancer Discov 2017;7:OF1.
19. Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016;5:e1253656. doi:10.1080/2162402X.2016.1253656. PMID:28180032.
20. Davenport AJ, Jenkins MR, Ritchie DS, Prince HM, Trapani JA, Kershaw MH, Darcy PK, Neeson PJ. CAR-T cells are serial killers. Oncoimmunology. 2015;4:e1053684. doi:10.1080/2162402X.2015.1053684. PMID:26587330.
21. Haskins-Coulter T, Southern J, Andrews N, Miller E. Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females. Hum Vaccin Immunother. 2017;13:1–9. doi:10.1080/21645515.2016.1277846. PMID:27636098.
22. Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, Salmeron J, McNeil S, Stapleton JT, Bouchard C, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16:1154–68. doi:10.1016/S1473-3099(16)30120-7.
23. Cuzick J. Gardasil 9 joins the fight against cervix cancer. Expert Rev Vaccines. 2015;14:1047–9. doi:10.1586/14760584.2015.1051470.
24. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA, Quiterio M, Lazcano-Ponce E. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)–The MAM Study. Vaccine. 2015;33:5640–6. doi:10.1016/j.vaccine.2015.08.072.
25. Toft L, Storgaard M, Muller M, Sehr P, Bonde J, Tolstrup M, Ostergaard L, Sogaard OS. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis. 2014;209:1165–73. doi:10.1093/infdis/jit657.
26. Qu C, Chen T, Fan C, Zhan Q, Wang Y, Lu J, Lu LL, Ni Z, Huang F, Yao H, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med. 2014;11:e1001774. doi:10.1371/journal.pmed.1001774. PMID:25549238.
27. Bloy N, Buque A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautes-Fridman C, Fucikova J, Galon J, Spisek R, et al. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015;4:e1026531. doi:10.1080/2162402X.2015.1026531. PMID:26155408.
28. Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Tartour E, Spisek R, et al. Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology. 2014;3:e963424. doi:10.4161/21624011.2014.963424. PMID:25941593.
29. Combe P, de Guillebon E, Thibault C, Granier C, Tartour E, Oudard S. Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. Oncoimmunology. 2015;4:e1001236. doi:10.1080/2162402X.2014.1001236. PMID:26155388.
30. Pol J, Bloy N, Buque A, Eggermont A, Cremer I, Sautes-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology. 2015;4:e974411. doi:10.4161/2162402X.2014.974411. PMID:26137405.
31. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Herve Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology. 2014;3:e28185. doi:10.4161/onci.28185. PMID:24800178.
32. Colluru VT, Johnson LE, Olson BM, McNeel DG. Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol. 2016;34:193–204. doi:10.1016/j.urolonc.2013.09.014.
33. Pierini S, Fang C, Rafail S, Facciponte JG, Huang J, De Sanctis F, Morgan MA, Uribe-Herranz M, Tanyi JL, Facciabene A. A Tumor Mitochondria Vaccine Protects against Experimental Renal Cell Carcinoma. J Immunol. 2015;195:4020–7. doi:10.4049/jimmunol.1500281.
34. Facciponte JG, Ugel S, De Sanctis F, Li C, Wang L, Nair G, Sehgal S, Raj A, Matthaiou E, Coukos G, et al. Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J Clin Invest. 2014;124:1497–511. doi:10.1172/JCI67382.
35. Bridle BW, Nguyen A, Salem O, Zhang L, Koshy S, Clouthier D, Chen L, Pol J, Swift SL, Bowdish DM, et al. Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination. J Immunol. 2016;196:4587–95. doi:10.4049/jimmunol.1600106.
36. Alonso-Camino V, Rajani K, Kottke T, Rommelfanger-Konkol D, Zaidi S, Thompson J, Pulido J, Ilett E, Donnelly O, Selby P, et al. The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site. Mol Ther. 2014;22:1936–48. doi:10.1038/mt.2014.134.
37. Pol JG, Zhang L, Bridle BW, Stephenson KB, Resseguier J, Hanson S, Chen L, Kazdhan N, Bramson JL, Stojdl DF, et al. Maraba virus as a potent oncolytic vaccine vector. Mol Ther. 2014;22:420–9. doi:10.1038/mt.2013.249.
38. Zhang L, Bridle BW, Chen L, Pol J, Spaner D, Boudreau JE, Rosen A, Bassett JD, Lichty BD, Bramson JL, et al. Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses. Blood. 2013;121:2432–9. doi:10.1182/blood-2012-06-438481.
39. Bridle BW, Clouthier D, Zhang L, Pol J, Chen L, Lichty BD, Bramson JL, Wan Y. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines. Oncoimmunology. 2013;2:e26013. doi:10.4161/onci.26013. PMID:24083086.
40. Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, Rommelfanger D, Ilett E, Pease L, Pandha H, et al. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol. 2012;30:337–43. doi:10.1038/nbt.2157.
41. Hellmann MD, Snyder A. Making It Personal: Neoantigen Vaccines in Metastatic Melanoma. Immunity. 2017;47:221–3. doi:10.1016/j.immuni.2017.08.001.
42. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217–21. doi:10.1038/nature22991.
43. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, Bukur V, Tadmor AD, Luxemburger U, Schrors B, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222–6. doi:10.1038/nature23003.
44. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11:509–24. doi:10.1038/nrclinonc.2014.111.
45. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909–15. doi:10.1038/nm1100.
46. Ferguson LR, Chen H, Collins AR, Connell M, Damia G, Dasgupta S, Malhotra M, Meeker AK, Amedei A, Amin A, et al. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol. 2015;35 Suppl:S5–S24.
47. Pierini S, Jordanov SH, Mitkova AV, Chalakov IJ, Melnicharov MB, Kunev KV, Mitev VI, Kaneva RP, Goranova TE. Promoter hypermethylation of CDKN2A, MGMT, MLH1, and DAPK genes in laryngeal squamous cell carcinoma and their associations with clinical profiles of the patients. Head Neck. 2014;36:1103–8. doi:10.1002/hed.23413.
48. Park YJ, Claus R, Weichenhan D, Plass C. Genome-wide epigenetic modifications in cancer. Prog Drug Res. 2011;67:25–49.
49. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99. doi:10.1016/j.cell.2010.01.025.
50. Vigneron N. Human Tumor Antigens and Cancer Immunotherapy. Biomed Res Int. 2015;2015:948501. doi:10.1155/2015/948501. PMID:26161423.
51. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14:135–46. doi:10.1038/nrc3670.
52. Kumai T, Matsuda Y, Ohkuri T, Oikawa K, Ishibashi K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. Oncoimmunology. 2015;4:e976077. doi:10.4161/2162402X.2014.976077. PMID:25949874.
53. Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget. 2015;6:15772–87. doi:10.18632/oncotarget.4694.
54. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33:1325–33. doi:10.1200/JCO.2014.57.4244.
55. Cicchelero L, Denies S, Devriendt B, de Rooster H, Sanders NN. Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells? Oncoimmunology. 2015;4:e1048413. doi:10.1080/2162402X.2015.1048413. PMID:26587315.
56. Lemay CG, Rintoul JL, Kus A, Paterson JM, Garcia V, Falls TJ, Ferreira L, Bridle BW, Conrad DP, Tang VA, et al. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther. 2012;20:1791–9. doi:10.1038/mt.2012.128.
57. Hirayama M, Nishimura Y. The present status and future prospects of peptide-based cancer vaccines. Int Immunol. 2016;28:319–28. doi:10.1093/intimm/dxw027.
58. Vandenberk L, Garg AD, Verschuere T, Koks C, Belmans J, Beullens M, Agostinis P, De Vleeschouwer S, Van Gool SW. Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. Oncoimmunology. 2016;5:e1083669. doi:10.1080/2162402X.2015.1083669. PMID:27057467.
59. Borch TH, Engell-Noerregaard L, Zeeberg Iversen T, Ellebaek E, Met O, Hansen M, Andersen MH, Thor Straten P, Svane IM. mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. Oncoimmunology. 2016;5:e1207842. doi:10.1080/2162402X.2016.1207842. PMID:27757300.
60. Ji J, Zhang Y, Chen WR, Wang X. DC vaccine generated by ALA-PDT-induced immunogenic apoptotic cells for skin squamous cell carcinoma. Oncoimmunology. 2016;5:e1072674. doi:10.1080/2162402X.2015.1072674. PMID:27471605.
61. Kyte JA, Aamdal S, Dueland S, Saeboe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G. Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. Oncoimmunology. 2016;5:e1232237. doi:10.1080/2162402X.2016.1232237. PMID:27999747.
62. Lundstrom K. RNA-based drugs and vaccines. Expert Rev Vaccines. 2015;14:253–63. doi:10.1586/14760584.2015.959932. PMID:25220891.
63. McNamara MA, Nair SK, Holl EK. RNA-Based Vaccines in Cancer Immunotherapy. J Immunol Res. 2015;2015:794528. doi:10.1155/2015/794528. PMID:26665011.
64. Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Tureci O, Sahin U. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 2010;70:9031–40. doi:10.1158/0008-5472.CAN-10-0699.
65. Thalmensi J, Pliquet E, Liard C, Escande M, Bestetti T, Julithe M, Kostrzak A, Pailhes-Jimenez AS, Bourges E, Loustau M, et al. Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response. Oncoimmunology. 2016;5:e1083670. doi:10.1080/2162402X.2015.1083670. PMID:27141336.
66. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines. 2012;11:189–209. doi:10.1586/erv.11.188.
67. Fu TM, Ulmer JB, Caulfield MJ, Deck RR, Friedman A, Wang S, Liu X, Donnelly JJ, Liu MA. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med. 1997;3:362–71.
68. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465–8. doi:10.1126/science.1690918.
69. Ruan Z, Yang Z, Wang Y, Wang H, Chen Y, Shang X, Yang C, Guo S, Han J, Liang H, et al. DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. J Immunother. 2009;32:486–91. doi:10.1097/CJI.0b013e3181a1d134.
70. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison M, Pardoll D, Wu L, Wu TC. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine. 2003;21:4036–42. doi:10.1016/S0264-410X(03)00275-5.
71. Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer. 2003;98:144–54. doi:10.1002/cncr.11462.
72. Andre F, Mir LM. DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther. 2004;11 Suppl 1:S33–42.
73. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol. 2010;2010:174378. doi:10.1155/2010/174378. PMID:20368780.
74. Yang B, Jeang J, Yang A, Wu TC, Hung CF. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 2014;10:3153–64. doi:10.4161/21645515.2014.980686.
75. Facciabene A, Aurisicchio L, Elia L, Palombo F, Mennuni C, Ciliberto G, La Monica N. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum Gene Ther. 2006;17:81–92. doi:10.1089/hum.2006.17.81.
76. Facciabene A, Aurisicchio L, Elia L, Palombo F, Mennuni C, Ciliberto G, La Monica N. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine. 2007;26:47–58. doi:10.1016/j.vaccine.2007.10.060. PMID:18055074.
77. Monie A, Tsen SW, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Expert Rev Vaccines. 2009;8:1221–35. doi:10.1586/erv.09.76.
78. Colluru VT, Zahm CD, McNeel DG. Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses. Oncoimmunology. 2016;5:e1223002. doi:10.1080/2162402X.2016.1223002. PMID:27853647.
79. Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res. 2015;75:5–10. doi:10.1158/0008-5472.CAN-14-2538.
80. Maby P, Galon J, Latouche JB. Frameshift mutations, neoantigens and tumor-specific CD8(+) T cells in microsatellite unstable colorectal cancers. Oncoimmunology. 2016;5:e1115943. doi:10.1080/2162402X.2015.1115943. PMID:27467916.
81. Polyakova A, Kuznetsova K, Moshkovskii S. Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens. Expert Rev Proteomics. 2015;12:533–41. doi:10.1586/14789450.2015.1070100.
82. Vitale I, Manic G, Senovilla L, Kroemer G, Galluzzi L. Karyotypic Aberrations in Oncogenesis and Cancer Therapy. Trends Cancer. 2015;1:124–35. doi:10.1016/j.trecan.2015.08.001.
83. Zhang X, Sharma PK, Peter Goedegebuure S, Gillanders WE. Personalized cancer vaccines: Targeting the cancer mutanome. Vaccine. 2017;35:1094–100. doi:10.1016/j.vaccine.2016.05.073.
84. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74. doi:10.1126/science.aaa4971.
85. Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125:3413–21. doi:10.1172/JCI80008.
86. Karasaki T, Nagayama K, Kawashima M, Hiyama N, Murayama T, Kuwano H, Nitadori J, Anraku M, Sato M, Miyai M, et al. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer. J Thorac Oncol. 2016;11:324–33. doi:10.1016/j.jtho.2015.11.006.
87. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515:572–6. doi:10.1038/nature14001.
88. Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, Zhang W, Sougnez C, Cibulskis K, Sidney J, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014;124:453–62. doi:10.1182/blood-2014-04-567933.
89. Li F, Chen C, Ju T, Gao J, Yan J, Wang P, Xu Q, Hwu P, Du X, Lizee G. Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination. Oncoimmunology. 2016;5:e1238539. doi:10.1080/2162402X.2016.1238539. PMID:28123873.
90. Williams JA. Improving DNA vaccine performance through vector design. Curr Gene Ther. 2014;14:170–89. doi:10.2174/156652321403140819122538.
91. Williams JA. Vector Design for Improved DNA Vaccine Efficacy, Safety and Production. Vaccines (Basel). 2013;1:225–49.
92. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8:108–20. doi:10.1038/nrc2326.
93. Stenler S, Blomberg P, Smith CI. Safety and efficacy of DNA vaccines: plasmids vs. minicircles. Hum Vaccin Immunother. 2014;10:1306–8. doi:10.4161/hv.28077.
94. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis. 2011;53:296–302. doi:10.1093/cid/cir334.
95. Robertson JS, Griffiths E. Assuring the quality, safety, and efficacy of DNA vaccines. Methods Mol Med. 2006;127:363–74.
96. Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology. 2013;2:e23803. doi:10.4161/onci.23803. PMID:23734328.
97. Ladomersky E, Genet M, Zhai L, Gritsina G, Lauing KL, Lulla RR, Fangusaro J, Lenzen A, Kumthekar P, Raizer JJ, et al. Improving vaccine efficacy against malignant glioma. Oncoimmunology. 2016;5:e1196311. doi:10.1080/2162402X.2016.1196311. PMID:27622066.
98. Nguyen-Hoai T, Pham-Duc M, Gries M, Dorken B, Pezzutto A, Westermann J. CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model. Cancer Gene Ther. 2016;23:162–7. doi:10.1038/cgt.2016.9.
99. Igoucheva O, Jonas R, Alexeev V. Chemokine-enhanced DNA vaccination in cancer immunotherapy. Oncoimmunology. 2013;2:e26092. doi:10.4161/onci.26092. PMID:24251079.
100. Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol. 2013;4:354. doi:10.3389/fimmu.2013.00354. PMID:24204366.
101. Kobiyama K, Jounai N, Aoshi T, Tozuka M, Takeshita F, Coban C, Ishii KJ. Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination. Vaccines (Basel). 2013;1:278–92.
102. Xue W, Metheringham RL, Brentville VA, Gunn B, Symonds P, Yagita H, Ramage JM, Durrant LG. SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade. Oncoimmunology. 2016;5:e1169353. PMID:27471648.
103. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205–14. PMID:25860605.
104. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61.
105. Konduri V, Li D, Halpert MM, Liang D, Liang Z, Chen Y, Fisher WE, Paust S, Levitt JM, Yao QC, et al. Chemo-immunotherapy mediates durable cure of orthotopic KrasG12D/p53−/− pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5:e1213933. PMID:27757308.
106. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111.
107. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015;28:690–714.
108. Chen CA, Ho CM, Chang MC, Sun WZ, Chen YL, Chiang YC, Syu MH, Hsieh CY, Cheng WF. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther. 2010;18:1233–43.
109. Veenstra JJ, Gibson HM, Freytag S, Littrup PJ, Wei WZ. In situ immunization via non-surgical ablation to prevent local and distant tumor recurrence. Oncoimmunology. 2015;4:e989762. PMID:25949901.
110. Seyedin SN, Tang C, Welsh JW. Author's view: radiation and immunotherapy as systemic therapy for solid tumors. Oncoimmunology. 2015;4:e986402. PMID:25949899.
111. Wennerberg E, Vanpouille-Box C, Bornstein S, Yamazaki T, Demaria S, Galluzzi L. Immune recognition of irradiated cancer cells. Immunol Rev. 2017;280:220–30.
112. Demaria S, Golden EB, Formenti SC. Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol. 2015;1:1325–32.
113. Demaria S, Coleman CN, Formenti SC. Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer. 2016;2:286–94.
114. Vacchelli E, Bloy N, Aranda F, Buque A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, et al. Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology. 2016;5:e1214790. PMID:27757313.
115. Galluzzi L, Bravo-San Pedro JM, Demaria S, Formenti SC, Kroemer G. Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. Nat Rev Clin Oncol. 2017;14:247–58.
116. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011;9:16–32.
117. Penault-Llorca F, Radosevic-Robin N. Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nat Rev Clin Oncol. 2016;13:487–503.
118. Xia J, Shi J, Wang P, Song C, Wang K, Zhang J, Ye H. Tumour-Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta-Analysis. Scand J Immunol. 2016;83:393–408.
119. Provinciali M, Barucca A, Orlando F, Pierpaoli E. Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span. Sci Rep. 2017;7:3078. PMID:28596550.
120. Lacalle RA, Blanco R, Carmona-Rodriguez L, Martin-Leal A, Mira E, Manes S. Chemokine Receptor Signaling and the Hallmarks of Cancer. Int Rev Cell Mol Biol. 2017;331:181–244.
121. Liu JY, Li F, Wang LP, Chen XF, Wang D, Cao L, Ping Y, Zhao S, Li B, Thorne SH, et al. CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma. Br J Cancer. 2015;113:747–55.
122. Chen S, Jiao J, Jiang D, Wan Z, Li L, Li K, Xu L, Zhou Z, Xu W, Xiao J. T-box transcription factor Brachyury in lung cancer cells inhibits macrophage infiltration by suppressing CCL2 and CCL4 chemokines. Tumour Biol. 2015;36:5881–90.
123. Marques C, Correia J, Ferreira F. HER2-positive feline mammary carcinoma. Aging (Albany NY). 2016;8:1574–5.
124. Hassan BB, Elshafae SM, Supsavhad W, Simmons JK, Dirksen WP, Sokkar SM, Rosol TJ. Feline Mammary Cancer. Vet Pathol. 2017;54:32–43.
125. Soares M, Madeira S, Correia J, Peleteiro M, Cardoso F, Ferreira F. Molecular based subtyping of feline mammary carcinomas and clinicopathological characterization. Breast. 2016;27:44–51.
126. Gibson HM, Veenstra JJ, Jones R, Vaishampayan U, Sauerbrey M, Bepler G, Lum L, Reyes J, Weise A, Wei WZ. Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination. Cancer Immunol Res. 2015;3:777–86.
127. Juillerat-Jeanneret L, Tafelmeyer P, Golshayan D. Fibroblast activation protein-alpha in fibrogenic disorders and cancer: more than a prolyl-specific peptidase? Expert Opin Ther Targets. 2017;21:977–91.
128. Wang Y, Hall RA, Lee M, Kamgar-Parsi A, Bi X, Baudry M. The tyrosine phosphatase PTPN13/FAP-1 links calpain-2, TBI and tau tyrosine phosphorylation. Sci Rep. 2017;7:11771. PMID:28924170.
129. Chen L, Qiu X, Wang X, He J. FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression. Biochem Biophys Res Commun. 2017;487:8–14.
130. Park CK, Jung WH, Koo JS. Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma. Breast Cancer Res Treat. 2016;159:55–69.
131. Jia J, Martin TA, Ye L, Jiang WG. FAP-alpha (Fibroblast activation protein-alpha) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway. BMC Cell Biol. 2014;15:16. PMID:24885257.
132. Xia Q, Zhang FF, Geng F, Liu CL, Xu P, Lu ZZ, Yu B, Wu H, Wu JX, Zhang HH, et al. Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein alpha by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model. Cancer Immunol Immunother. 2016;65:613–24.
133. Pol J, Buque A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, et al. Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology. 2016;5:e1117740. PMID:27057469.
134. Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, Kalli KR, Goode EL, Block MS, Cannon MJ, et al. IL-10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Res. 2017. PMID:28993412.
135. Schmetterer KG, Pickl WF. The IL-10/STAT3 axis: Contributions to immune tolerance by thymus and peripherally derived regulatory T-cells. Eur J Immunol. 2017;47:1256–65.
136. Mittal SK, Roche PA. Suppression of antigen presentation by IL-10. Curr Opin Immunol. 2015;34:22–7.
137. Xia Q, Geng F, Zhang FF, Liu CL, Xu P, Lu ZZ, Zhang HH, Kong W, Yu XH. Enhancement of fibroblast activation protein alpha-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice. Vaccine. 2016;34:4526–35.
138. Unanue ER. Altered peptide ligands make their entry. J Immunol. 2011;186:7–8.
139. Heninger E, Krueger TE, Thiede SM, Sperger JM, Byers BL, Kircher MR, Kosoff D, Yang B, Jarrard DF, McNeel DG, et al. Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget. 2016;7:84359–74.
140. Bloom JE, McNeel DG. SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. Oncotarget. 2016;7:50997–1011.
141. Smith HA, Rekoske BT, McNeel DG. DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. Vaccine. 2014;32:1707–15.
142. Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DG. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol Res. 2015;3:946–55.
143. Gentzler R, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL, Jr., Rahma OE. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy. 2016;8:583–600.
144. Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68:267–79.
145. Drutman SB, Trombetta ES. Dendritic cells continue to capture and present antigens after maturation in vivo. J Immunol. 2010;185:2140–6.
146. Moody DB, Cotton RN. Four pathways of CD1 antigen presentation to T cells. Curr Opin Immunol. 2017;46:127–33.
147. Galluzzi L, Zitvogel L, Kroemer G. Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. Cancer Immunol Res. 2016;4:895–902.
148. Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E, Knuth A, Chen YT, Old LJ. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1–30.
149. Metheringham RL, Pudney VA, Gunn B, Towey M, Spendlove I, Durrant LG. Antibodies designed as effective cancer vaccines. MAbs. 2009;1:71–85.
150. Durrant LG, Pudney VA, Spendlove I. Using monoclonal antibodies to stimulate antitumor cellular immunity. Expert Rev Vaccines. 2011;10:1093–106.
151. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14:409–26.
152. Ghadjar P, Rubie C, Aebersold DM, Keilholz U. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer. 2009;125:741–5. PMID:19480006.
153. Gordy JT, Luo K, Zhang H, Biragyn A, Markham RB. Fusion of the dendritic cell-targeting chemokine MIP3alpha to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model. J Immunother Cancer. 2016;4:96. PMID:28018602.
154. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229:152–72.
155. Lee GH, Askari A, Malietzis G, Bernardo D, Clark SK, Knight SC, Al-Hassi HO. The role of CD40 expression in dendritic cells in cancer biology; a systematic review. Curr Cancer Drug Targets. 2014;14:610–20.
156. Gupta S, Termini JM, Rivas Y, Otero M, Raffa FN, Bhat V, Farooq A, Stone GW. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. Vaccine. 2015;33:4798–806.
157. Watt B, van Niel G, Raposo G, Marks MS. PMEL: a pigment cell-specific model for functional amyloid formation. Pigment Cell Melanoma Res. 2013;26:300–15.
158. Rizos K, Lattemann CT, Bumann D, Meyer TF, Aebischer T. Autodisplay: efficacious surface exposure of antigenic UreA fragments from Helicobacter pylori in Salmonella vaccine strains. Infect Immun. 2003;71:6320–8.
159. Rodriguez-Cerdeira C, Gregorio MC, Lopez-Barcenas A, Sanchez-Blanco E, Sanchez-Blanco B, Fabbrocini G, Bardhi B, Sinani A, Guzman RA. Advances in Immunotherapy for Melanoma: A Comprehensive Review. Mediators Inflamm. 2017;2017:3264217. PMID:28848246.
160. Braunlein E, Krackhardt AM. Tools to define the melanoma-associated immunopeptidome. Immunology. 2017. PMID:28755382.
161. Mei Y, Zhao L, Liu Y, Gong H, Song Y, Lei L, Zhu Y, Jin Z, Ma S, Hu B, et al. Combining DNA Vaccine and AIDA-1 in Attenuated Salmonella Activates Tumor-Specific CD4+ and CD8+ T-cell Responses. Cancer Immunol Res. 2017;5:503–14.
162. Stermann A, Huebener N, Seidel D, Fest S, Eschenburg G, Stauder M, Schramm A, Eggert A, Lode HN. Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice. Cancer Immunol Immunother. 2015;64:1215–27.
163. Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene. 2006;25:6758–80.
164. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25:280–8.
165. Afonina IS, Zhong Z, Karin M, Beyaert R. Limiting inflammation-the negative regulation of NF-kappaB and the NLRP3 inflammasome. Nat Immunol. 2017;18:861–9.
166. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev. 2012;246:379–400.
167. Galvez-Cancino F, Roco J, Rojas-Colonelli N, Flores C, Murgas P, Cruz-Gomez S, Oyarce C, Varas-Godoy M, Sauma D, Lladser A. A short hairpin RNA-based adjuvant targeting NF-kappaB repressor IkappaBalpha promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination. Vaccine. 2017;35:4148–54.
168. Kailashiya C, Sharma HB, Kailashiya J. Telomerase based anticancer immunotherapy and vaccines approaches. Vaccine. 2017;35:5768–75.
169. Gomez DL, Armando RG, Cerrudo CS, Ghiringhelli PD, Gomez DE. Telomerase as a Cancer Target. Development of New Molecules. Curr Top Med Chem. 2016;16:2432–40.
170. Qian Y, Yang L, Cao S. Telomeres and telomerase in T cells of tumor immunity. Cell Immunol. 2014;289:63–9. PMID:24727158.
171. Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 2013;39:444–56.
172. Zahm CD, Colluru VT, McNeel DG. DNA vaccines for prostate cancer. Pharmacol Ther. 2017;174:27–42.
173. Patel SP, Osada T, Lyerly HK, Morse MA. Designing effective vaccines for colorectal cancer. Immunotherapy. 2014;6:913–26.
174. Yan WL, Shen KY, Tien CY, Chen YA, Liu SJ. Recent progress in GM-CSF-based cancer immunotherapy. Immunotherapy. 2017;9:347–60.
175. Yu TW, Chueh HY, Tsai CC, Lin CT, Qiu JT. Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines. Hum Vaccin Immunother. 2016;12:3020–8.
176. Clive KS, Tyler JA, Clifton GT, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines. 2010;9:519–25.
177. Olson BM, Bradley ES, Sawicki T, Zhong W, Ranheim EA, Bloom JE, Colluru VT, Johnson LE, Rekoske BT, Eickhoff JC, et al. Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD). Prostate. 2017;77:812–21.
178. Camarda R, Williams J, Goga A. In vivo Reprogramming of Cancer Metabolism by MYC. Front Cell Dev Biol. 2017;5:35. PMID:28443280.
179. Casey SC, Baylot V, Felsher DW. MYC: Master Regulator of Immune Privilege. Trends Immunol. 2017;38:298–305.
180. Cross RS, Malaterre J, Davenport AJ, Carpinteri S, Anderson RL, Darcy PK, Ramsay RG. Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. Clin Transl Immunology. 2015;4:e30. PMID:25671128.
181. Xiang B, Baybutt TR, Berman-Booty L, Magee MS, Waldman SA, Alexeev VY, Snook AE. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells. J Immunol. 2017;198:3507–14.
182. Haedicke J, Iftner T. Human papillomaviruses and cancer. Radiother Oncol. 2013;108:397–402.
183. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Munoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26 Suppl 10:K1–16.
184. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113:3036–46.
185. Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol. 2001;166:5917–24.
186. Lee HJ, Yoon JK, Heo Y, Cho H, Cho Y, Gwon Y, Kim KC, Choi J, Lee JS, Oh YK, et al. Therapeutic potential of an AcHERV-HPV L1 DNA vaccine. J Microbiol. 2015;53:415–20.
187. Ma Y, Yang A, Peng S, Qiu J, Farmer E, Hung CF, Wu TC. Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model. Vaccine. 2017;35:3850–8.
188. Bloy N, Garcia P, Laumont CM, Pitt JM, Sistigu A, Stoll G, Yamazaki T, Bonneil E, Buque A, Humeau J, et al. Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunol Rev. 2017;280:165–74.
189. Galluzzi L, Kroemer G. Calreticulin and type I interferon: An unsuspected connection. Oncoimmunology. 2017;6:e1288334. PMID:28405522.
190. Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, Salek C, Strnad P, Kroemer G, Galluzzi L, et al. Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol. 2015;6:402. PMID:26300886.
191. Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I, Vosahlikova S, Klouckova J, Church SE, Cremer I, et al. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood. 2016;128:3113–24.
192. Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity. 1996;5:103–14. doi:10.1016/S1074-7613(00)80487-2.
193. Sun Y, Peng S, Qiu J, Miao J, Yang B, Jeang J, Hung CF, Wu TC. Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors. Gene Ther. 2015;22:528–35. doi:10.1038/gt.2015.17.
194. Perez-Trujillo JJ, Garza-Morales R, Barron-Cantu JA, Figueroa-Parra G, Garcia-Garcia A, Rodriguez-Rocha H, Garcia-Juarez J, Munoz-Maldonado GE, Saucedo-Cardenas O, Montes-De-Oca-Luna R, et al. DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect. Oncol Lett. 2017;13:1569–74.
195. Wu CC, Wu FC, Hsu YT, Hsiao YC, Yang YC, Chang CA, Chang CL. Enhanced anti-tumor therapeutic efficacy of DNA vaccine by fusing the E7 gene to BAFF in treating human papillomavirus-associated cancer. Oncotarget. 2017;8:33024–36.
196. Sun YY, Peng S, Han L, Qiu J, Song L, Tsai Y, Yang B, Roden RB, Trimble CL, Hung CF, et al. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract. Clin Cancer Res. 2016;22:657–69. doi:10.1158/1078-0432.CCR-15-0234.
197. Ugel S, Facciponte JG, De Sanctis F, Facciabene A. Targeting tumor vasculature: expanding the potential of DNA cancer vaccines. Cancer Immunol Immunother. 2015;64:1339–48. doi:10.1007/s00262-015-1747-8. PMID:26267042.
198. Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, et al. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. Oncoimmunology. 2015;4:e1001217. doi:10.1080/2162402X.2014.1001217. PMID:26137397.
199. Gao J, Fan L, Ma W, Xiao H. Synergistic antitumor effect of a human papillomavirus DNA vaccine harboring E6E7 fusion gene and vascular endothelial growth factor receptor 2 gene. Microbiol Immunol. 2016;60:626–33. doi:10.1111/1348-0421.12408.
200. Ahrends T, Babala N, Xiao Y, Yagita H, van Eenennaam H, Borst J. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination. Cancer Res. 2016;76:2921–31. doi:10.1158/0008-5472.CAN-15-3130.
201. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol. 2009;27:4047–54. doi:10.1200/JCO.2008.19.9968.
202. Johnson LE, Olson BM, McNeel DG. Pretreatment antigen-specific immunity and regulation–association with subsequent immune response to anti-tumor DNA vaccination. J Immunother Cancer. 2017;5:56. doi:10.1186/s40425-017-0260-3. PMID:28716080.
203. McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin Cancer Res. 2014;20:3692–704. doi:10.1158/1078-0432.CCR-14-0169.
204. McNeel D, Eickhoff J, Jeraj R, Staab M, Straus J, Rekoske B, Liu G. Meeting Library | DNA vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC). Available at: http://meetinglibrary.asco.org/record/140943/abstract. ASCO University 2017.
205. Ottensmeier C, Bowers M, Hamid D, Maishman T, Regan S, Wood W, Cazaly A, Stanton L. Wilms' tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN). Efficacy Mech Eval. 2016;3. doi:10.3310/eme03030.
206. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, et al. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017;5:35. doi:10.1186/s40425-017-0238-1. PMID:28428884.
207. Zitvogel L, Rusakiewicz S, Routy B, Ayyoub M, Kroemer G. Immunological off-target effects of imatinib. Nat Rev Clin Oncol. 2016;13:431–46. doi:10.1038/nrclinonc.2016.41.
208. Capdeville R, Silberman S. Imatinib: a targeted clinical drug development. Semin Hematol. 2003;40:15–20. doi:10.1053/shem.2003.50037.
209. Teixeira L, Medioni J, Doucet L, Culine S, Oudard S, Adotevi O, Dragon Durey M, Kiladjian J, Brizard M, Bourré L, et al. Meeting Library | Results of a first-in-human phase I study of INVAC-1, an optimized plasmid DNA encoding an inactive form of human telomerase reverse transcriptase (hTERT), in patients with advanced solid tumors. Available at: http://meetinglibrary.asco.org/record/145093/abstract. ASCO University 2017.
210. Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386:2078–88. doi:10.1016/S0140-6736(15)00239-1.
211. Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F. The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets. Trends Microbiol. 2017. doi:10.1016/j.tim.2017.07.007. PMID: 28823569.
212. Tomaic V. Functional Roles of E6 and E7 Oncoproteins in HPV-Induced Malignancies at Diverse Anatomical Sites. Cancers (Basel). 2016;8. doi:10.3390/cancers8100095. PMID:27775564.
213. Aggarwal C, Cohen R, Morrow M, Bauml J, Weinstein G, Boyer J, Shen X, Yan J, Goldenberg J, Nashit D, et al. Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results. J Immunother Cancer. 2015;3:P426. doi:10.1186/2051-1426-3-S2-P426.
214. Shore ND, Heath EI, Nordquist LT, Cheng HH, Bhatt K, Carroll N, Kraynyak K, Lee J, Tornout JV, Sacchetta B, et al. A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer. J Clin Oncol. 2017;35:80-. doi:10.1200/JCO.2017.35.6_suppl.80.
215. Patel PM, Durrant LG, Ottensmeier C, Mulatero C, Lorigan P, Plummer R, Cunnell M, Metheringham R, Brentville V, Machado L, et al. Phase I trial of ImmunoBody in melanoma patients. J Clin Oncol. 2014;32:3061-.
216. Patel P, Ottensmeier C, Mulatero C, Lorigan P, Plummer R, Hannaman D, Cunnell M, Metheringham R, Brentville V, Daniels I, et al. Meeting Library | An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients. Available at: http://meetinglibrary.asco.org/record/112633/abstract. ASCO University 2015.
217. Xue W, Brentville VA, Symonds P, Cook KW, Yagita H, Metheringham RL, Durrant LG. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. Oncotarget. 2016;7:83088–100.
218. Miles B, Safran HP, Monk BJ. Therapeutic options for treatment of human papillomavirus-associated cancers–novel immunologic vaccines: ADXS11-001. Gynecol Oncol Res Pract. 2017;4:10. doi:10.1186/s40661-017-0047-8. PMID:28725449.
219. Miles BA, Monk BJ, Safran HP. Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy. Gynecol Oncol Res Pract. 2017;4:9. doi:10.1186/s40661-017-0046-9. PMID:28588899.
220. Huh W, Dizon D, Powell M, Leath C, Landrum L, Tanner E, Higgins R, Ueda S, McHale M, Monk B, et al. Meeting Library | ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage I of the phase II GOG/NRG0265 study. Available at: http://meetinglibrary.asco.org/record/125327/abstract. ASCO University 2016.
221. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123:321–34. doi:10.1016/j.cell.2005.08.032. PMID:16239148.
222. Iribarren K, Bloy N, Buque A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, et al. Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology. 2016;5:e1088631. doi:10.1080/2162402X.2015.1088631. PMID:27141345.
223. Buque A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, et al. Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology. 2016;5:e1149674. doi:10.1080/2162402X.2016.1149674. PMID:27471617.
224. Maldonado L, Teague JE, Morrow MP, Jotova I, Wu TC, Wang C, Desmarais C, Boyer JD, Tycko B, Robins HS, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med. 2014;6:221ra13. doi:10.1126/scitranslmed.3007323.
225. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009;15:361–7. doi:10.1158/1078-0432.CCR-08-1725. PMID:19417015.
226. Alvarez RD, Huh WK, Bae S, Lamb LS, Jr., Conner MG, Boyer J, Wang C, Hung CF, Sauter E, Paradis M, et al. A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). Gynecol Oncol. 2016;140:245–52. doi:10.1016/j.ygyno.2015.11.026.
227. Lakshmanan I, Ponnusamy MP, Macha MA, Haridas D, Majhi PD, Kaur S, Jain M, Batra SK, Ganti AK. Mucins in lung cancer: diagnostic, prognostic, and therapeutic implications. J Thorac Oncol. 2015;10:19–27. doi:10.1097/JTO.0000000000000404.
228. David JM, Hamilton DH, Palena C. MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition. Oncoimmunology. 2016;5:e1117738. doi:10.1080/2162402X.2015.1117738. PMID:27141403.
229. Situ D, Wang J, Ma Y, Zhu Z, Hu Y, Long H, Rong T. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol. 2011;28 Suppl 1:S596–604.
230. Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016;17:212–23. doi:10.1016/S1470-2045(15)00483-0.
231. Quoix E, Forget F, Papai-Szekely Z, Ottensmeier C, Felip E, Crino L, Szczesna A, Tavernaro A, Lacoste G, Bastien B, et al. Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy. J Clin Oncol. 2015;33:3034-.
232. Snook AE, Magee MS, Marszalowicz GP, Schulz S, Waldman SA. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C. Cancer Immunol Immunother. 2012;61:713–23. doi:10.1007/s00262-011-1133-0.
233. Snook AE, Li P, Stafford BJ, Faul EJ, Huang L, Birbe RC, Bombonati A, Schulz S, Schnell MJ, Eisenlohr LC, et al. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res. 2009;69:3537–44. doi:10.1158/0008-5472.CAN-08-3386.
234. Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, et al. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst. 2008;100:950–61. doi:10.1093/jnci/djn178.
235. Snook AE, Eisenlohr LC, Rothstein JL, Waldman SA. Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen. Clin Pharmacol Ther. 2007;82:734–9. doi:10.1038/sj.clpt.6100369.
236. Rosa DS, Tzelepis F, Cunha MG, Soares IS, Rodrigues MM. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunol Lett. 2004;92:259–68. doi:10.1016/j.imlet.2004.01.006.
237. Franke ED, Hoffman SL, Sacci JB, Jr., Wang R, Charoenvit Y, Appella E, Chesnut R, Alexander J, Del Guercio MF, Sette A. Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites. Vaccine. 1999;17:1201–5. doi:10.1016/S0264-410X(98)00341-7.
238. Snook A, Baybutt T, Mastrangelo M, Lewis N, Goldstein S, Kraft W, Oppong Y, Hyslop T, Myers R, Alexeev V, et al. A Phase I study of AD5-GUCY2C-PADRE in stage I and II colon cancer patients. J Immunother Cancer. 2015;3:P450. doi:10.1186/2051-1426-3-S2-P450.
239. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18:1001–11. doi:10.1517/13543780902997928.
240. Culig Z. Targeting the androgen receptor in prostate cancer. Expert Opin Pharmacother. 2014;15:1427–37. doi:10.1517/14656566.2014.915313.
241. Geary SM, Salem AK. Prostate cancer vaccines: Update on clinical development. Oncoimmunology. 2013;2:e24523. doi:10.4161/onci.24523. PMID:23762812.
242. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, Costello JC, Theodorescu D, Cech TR. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science. 2015;347:1006–10. doi:10.1126/science.1260200.
243. Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 2014;74:2907–12. doi:10.1158/0008-5472.CAN-14-0337.
244. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2:112–20. doi:10.1158/2326-6066.CIR-13-0170.
245. Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32:643–71. doi:10.1007/s10555-013-9444-6.
246. Wang L, Ma N, Okamoto S, Amaishi Y, Sato E, Seo N, Mineno J, Takesako K, Kato T, Shiku H. Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology. 2016;5:e1211218. doi:10.1080/2162402X.2016.1211218. PMID:27757303.
247. Strothmeyer AM, Papaioannou D, Duhren-von Minden M, Navarrete M, Zirlik K, Heining-Mikesch K, Veelken H. Comparative analysis of predicted HLA binding of immunoglobulin idiotype sequences indicates T cell-mediated immunosurveillance in follicular lymphoma. Blood. 2010;116:1734–6. doi:10.1182/blood-2010-02-270199.
248. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer. 2009;9:675–81. doi:10.1038/nrc2717.
249. Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR, Lee CW, Kim S, Woo JW, Park KS, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317. doi:10.1038/ncomms6317. PMID:25354725.
250. Lau-Kilby AW, Kretz CC, Pechhold S, Price JD, Dorta S, Ramos H, Trinchieri G, Tarbell KV. Interleukin-2 inhibits FMS-like tyrosine kinase 3 receptor ligand (flt3L)-dependent development and function of conventional and plasmacytoid dendritic cells. Proc Natl Acad Sci U S A. 2011;108:2408–13. doi:10.1073/pnas.1009738108.
251. Weigel BJ, Nath N, Taylor PA, Panoskaltsis-Mortari A, Chen W, Krieg AM, Brasel K, Blazar BR. Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. Blood. 2002;100:4169–76. doi:10.1182/blood-2002-04-1063.
252. Vonderheide RH, Aggarwal C, Bajor DL, Goldenberg J, Loch C, Lee JC, Yan J, Morrow MP, DeMichele A, Langer CJ, et al. Study of hTERT and IL-12 DNA immunotherapy using electroporation in patients with solid tumors after definitive surgery and adjuvant therapy. J Clin Oncol. 2015;33:TPS3104–TPS.
253. Kang J, Galluzzi L. PD-L1 blockade for urothelial carcinoma. Oncoimmunology. 2017;6:e1334028. doi:10.1080/2162402X.2017.1334028. PMID:28811979.
254. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017. doi:10.1056/NEJMoa1709937. PMID:28885881.
255. Brower V. Anti-PD-L1 inhibitor durvalumab in bladder cancer. Lancet Oncol. 2016;17:e275. doi:10.1016/S1470-2045(16)30242-X. PMID:27321156.
256. McCann KJ, Godeseth R, Chudley L, Mander A, Di Genova G, Lloyd-Evans P, Kerr JP, Malykh VB, Jenner MW, Orchard KH, et al. Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. Cancer Immunol Immunother. 2015;64:1021–32. doi:10.1007/s00262-015-1703-7.
257. Lopez-Requena A, Burrone OR, Cesco-Gaspere M. Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins. Front Oncol. 2012;2:159. doi:10.3389/fonc.2012.00159. PMID:23162790.
258. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 2002;62:5845–52.
259. Meleshko AN, Petrovskaya NA, Savelyeva N, Vashkevich KP, Doronina SN, Sachivko NV. Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma. Hum Vaccin Immunother. 2017;13:1–6. doi:10.1080/21645515.2017.1285477.
260. Formenti SC, Golden EB, Goldberg JD, Li X, Taff J, Fenton-Kerimian MB, Chandrasekhar S, Demaria S, Novik Y. Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer. Oncoimmunology. 2017;6:e1274479. doi:10.1080/2162402X.2016.1274479. PMID:28405497.
261. Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology. 2015;4:e985930. doi:10.4161/2162402X.2014.985930. PMID:26405612.
262. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862–8.
263. Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother. 2014;63:225–34. doi:10.1007/s00262-013-1505-8.
264. Papasavvas E, Surrey LF, Glencross DK, Azzoni L, Joseph J, Omar T, Feldman MD, Williamson AL, Siminya M, Swarts A, et al. High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women. Oncoimmunology. 2016;5:e1128612. doi:10.1080/2162402X.2015.1128612. PMID:27467943.
265. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–83. doi:10.1038/onc.2011.384.
266. Zinner R, Visseren-Grul C, Spigel DR, Obasaju C. Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review). Int J Oncol. 2016;48:13–27.
267. Choy H, Gerber DE, Bradley JD, Iyengar P, Monberg M, Treat J, Govindan R, Koustensis A, Barker S, Obasaju C. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. Lung Cancer. 2015;87:232–40. doi:10.1016/j.lungcan.2014.12.003.
268. Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J, Jr., Cao D, et al. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015;121:883–92. doi:10.1002/cncr.29132.